1. Agios Pharmaceuticals, Inc. (2018a) A phase 1, open-label, single-dose study to evaluate the pharmacokinetics, safety, and tolerability of AG-120 (Ivosidenib) in subjects with mild or moderate hepatic impairment or normal hepatic function. clinicaltrials.gov
2. Agios Pharmaceuticals, Inc. (2018b) Expanded access program for Ivosidenib (AG-120) monotherapy in patients with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. clinicaltrials.gov
3. Agios Pharmaceuticals, Inc. (2019) A phase I, multicenter, open-label, dose-escalation and expansion, safety, pharmacokinetic, pharmacodynamic, and clinical activity study of orally administered AG-881 in patients with advanced hematologic malignancies with an IDH1 and/or IDH2 mutation. clinicaltrials.gov
4. Agios Pharmaceuticals, Inc. (2020a) A phase 1, multicenter, randomized, controlled, open-label, perioperative study of AG-120 and AG-881 in subjects with recurrent, non-enhancing, IDH1 mutant, low grade glioma. clinicaltrials.gov
5. Agios Pharmaceuticals, Inc. (2020b) A phase 1, multicenter, open-label, dose-escalation and expansion, safety, pharmacokinetic, pharmacodynamic, and clinical activity study of orally administered AG-881 in patients with advanced solid tumors, including gliomas, with an IDH1 and/or IDH2 mutation. clinicaltrials.gov